HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Integrative Medicine Council To Focus On Education, Public Policy

This article was originally published in The Tan Sheet

Executive Summary

One of the National Integrative Medicine Council's top priorities is to play an intermediary role between medical schools looking to offer integrative medicine programs and legislators seeking to reauthorize the Public Health Service Act during the 107th Congress, according to Executive Director Matt Russell.

You may also be interested in...



NCCAM Allocates $3 Mil. For CAM Integration Research Grants

The National Center for Complementary & Alternative Medicine is committing $3 mil. in FY 2001 to fund nine new grants for research investigating strategies to integrate CAM with conventional medicine.

White House CAM Commission Debates Medical Education

The current status and potential of complementary and alternative medicine education in medical schools were discussed at the inaugural meeting of the White House Commission on Complementary & Alternative Medicine Policy in Washington, D.C. July 13-14.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel